Literature DB >> 9038605

Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas.

C Hagel1, G Laking, R Laas, S Scheil, R Jung, K Milde-Langosch, D K Stavrou.   

Abstract

Paraffin embedded tissue of 84 oligodendrogliomas (63 primary tumours, 21 recurrences), 21 glioblastomas with oligodendroglial growth pattern (15 primaries, 6 recurrences) and 17 mixed gliomas was investigated for the presence of mutations in exons 5-9 by means of single stranded conformation polymorphism (SCCP), temperature gradient gel electrophoresis (TGGE) and direct DNA sequencing. In parallel, p53 protein accumulation was determined by means of immunohistochemistry. The percentage of mutations was found to be higher than previously reported (6 of 44 grade II oligodendrogliomas, 4 of 19 grade III oligodendrogliomas, 4 of 15 glioblastomas). In 4 cases, the mutations lead to distinct changes in the primary or secondary structure of the protein (cysteine-->tyrosine, proline-->leucine) and were associated with marked accumulation of p53 protein. A significant correlation between p53 protein accumulation and TP53 gene aberrations was found (P < 0.001), although p53 protein accumulation was detected more often than TP53 gene anomalies, indicating that factors other than TP53 gene mutation may also lead to a p53 protein accumulation in the tumour cells. A significant correlation was found for p53 protein accumulation and tumour grade but not TP53 gene mutations. In conclusion, evaluation of p53 protein accumulation reflected the clinical course of oligodendrogliomas better than the mere presence of TP53 gene mutations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9038605     DOI: 10.1016/s0959-8049(96)00259-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

1.  Molecular profile of oligodendrogliomas in young patients.

Authors:  Vaishali Suri; Prerana Jha; Shipra Agarwal; Pankaj Pathak; Mehar Chand Sharma; Vikas Sharma; Sudhanshu Shukla; Kumaravel Somasundaram; Ashok Kumar Mahapatra; Shashank Sharad Kale; Chitra Sarkar
Journal:  Neuro Oncol       Date:  2011-10       Impact factor: 12.300

2.  Proliferation and apoptosis in long-term surviving low grade gliomas in relation to radiotherapy.

Authors:  Mart A A M Heesters; Jan Koudstaal; K Gwan Go; Willemina M Molenaar
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

3.  TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas.

Authors:  Emeline Gillet; Agusti Alentorn; Brahima Doukouré; Emeline Mundwiller; Hinke F van Thuijl; Hinke van Thuij; Jaap C Reijneveld; José Alfonso Meza Medina; Amélie Liou; Yannick Marie; Karima Mokhtari; Khê Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Ahmed Idbaih
Journal:  J Neurooncol       Date:  2014-03-04       Impact factor: 4.130

4.  Chromosomal Aberrations in Canine Gliomas Define Candidate Genes and Common Pathways in Dogs and Humans.

Authors:  Peter J Dickinson; Dan York; Robert J Higgins; Richard A LeCouteur; Nikhil Joshi; Danika Bannasch
Journal:  J Neuropathol Exp Neurol       Date:  2016-05-31       Impact factor: 3.685

5.  The predictive capability of immunohistochemistry and DNA sequencing for determining TP53 functional mutation status: a comparative study of 41 glioblastoma patients.

Authors:  Aarash K Roshandel; Christopher M Busch; Jennifer Van Mullekom; Joshua A Cuoco; Cara M Rogers; Lisa S Apfel; Eric A Marvin; Harald W Sontheimer; Robyn A Umans
Journal:  Oncotarget       Date:  2019-10-22

6.  IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival.

Authors:  Severina Leu; Stefanie von Felten; Stephan Frank; Erik Vassella; Istvan Vajtai; Elisabeth Taylor; Marianne Schulz; Gregor Hutter; Jürgen Hench; Philippe Schucht; Jean-Louis Boulay; Luigi Mariani
Journal:  Neuro Oncol       Date:  2013-02-13       Impact factor: 13.029

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.